Abstract
Objective: This study aimed to compare robotic pancreatoduodenectomy (RPD) with laparoscopic pancreatoduodenectomy (LPD) in operative and oncologic outcomes. Background: Previous studies comparing RPD with LPD have only been carried out in small, single-center studies with variable quality. Methods: Consecutive patients from nine centers in China who underwent RPD or LPD between 2015 and 2022 were included. A 1:1 propensity score matching (PSM) was used to minimize bias. Results: Of the 2255 patients, 1158 underwent RPD, and 1097 underwent LPD. After PSM, 1006 patients were enrolled in each group. The RPD group had significantly shorter operative time (270.0 vs 305.0 minutes, P<0.001), lower intraoperative blood transfusion rate (5.9% vs 12.0%, P<0.001), lower conversion rate (3.8% vs 6.7%, P=0.004), and higher vascular reconstruction rate (7.9% vs 5.6%, P=0.040) than the LPD group. There were no significant differences in estimated blood loss, postoperative length of stay, perioperative complications, and 90-day mortality. Patients who underwent vascular reconstruction had similar outcomes between the 2 groups, although they had significantly lower estimated blood loss (300.0 vs 360.0 mL; P=0.021) in the RPD group. Subgroup analysis on pancreatic ductal adenocarcinoma found no significant differences between the 2 groups in median recurrence-free survival (14.3 vs 15.3 mo, P=0.573) and overall survival (24.1 vs 23.7 mo, P=0.710). Conclusions: In experienced hands, both RPD and LPD are safe and feasible procedures with similar surgical outcomes. RPD had a perioperative advantage over LPD, especially in vascular reconstruction. For pancreatic ductal adenocarcinoma patients, RPD resulted in similar oncological and survival outcomes as LPD.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call